ChromaDex’s Patented Nicotinamide Riboside (NR) Ingredient, Niagen®, Featured as the Hero Ingredient in Longevity.Technology’s Inaugural Longevity Supplement
ChromaDex Corp. (NASDAQ: CDXC) announces that its patented nicotinamide riboside (NR) ingredient, Niagen®, has been selected as the key ingredient in Longevity.Technology's new supplement. Niagen, recognized as the gold standard for NAD+ supplementation, is backed by over 30 peer-reviewed human clinical studies showing benefits in cellular, brain, heart, and muscle health. The company's intellectual property portfolio includes 90+ owned and licensed patents. Niagen is available through business partnerships and is the active ingredient in ChromaDex's Tru Niagen brand, currently the leading healthy-aging NAD+ supplement in the United States.
ChromaDex Corp. (NASDAQ: CDXC) annuncia che il suo ingrediente brevettato nicotinamide riboside (NR), Niagen®, è stato selezionato come ingrediente principale nel nuovo supplemento di Longevity.Technology. Niagen, riconosciuto come il gold standard per il supporto al NAD+, è sostenuto da oltre 30 studi clinici umani peer-reviewed che dimostrano benefici per la salute cellulare, del cervello, del cuore e dei muscoli. Il portafoglio di proprietà intellettuale dell'azienda comprende oltre 90 brevetti di proprietà e in licenza. Niagen è disponibile attraverso partnership commerciali ed è l'ingrediente attivo nel marchio Tru Niagen di ChromaDex, attualmente il principale integratore per un invecchiamento sano a base di NAD+ negli Stati Uniti.
ChromaDex Corp. (NASDAQ: CDXC) anuncia que su ingrediente patentado nicotinamida ribósido (NR), Niagen®, ha sido seleccionado como el ingrediente clave en el nuevo suplemento de Longevity.Technology. Niagen, reconocido como el estándar de oro para la suplementación de NAD+, cuenta con el respaldo de más de 30 estudios clínicos humanos revisados por pares que demuestran beneficios en la salud celular, cerebral, cardíaca y muscular. La cartera de propiedad intelectual de la empresa incluye más de 90 patentes propias y licenciadas. Niagen está disponible a través de asociaciones comerciales y es el ingrediente activo de la marca Tru Niagen de ChromaDex, actualmente el principal suplemento de NAD+ para el envejecimiento saludable en los Estados Unidos.
ChromaDex Corp. (NASDAQ: CDXC)는 자사의 특허받은 니코틴아미드 리보사이드(NR) 성분인 Niagen®이 Longevity.Technology의 새로운 보충제의 핵심 성분으로 선정되었다고 발표했습니다. Niagen은 NAD+ 보충제의 황금 기준으로 인정받으며, 세포, 뇌, 심장 및 근육 건강에 대한 이점을 보여주는 30개 이상의 동료 검토된 임상 연구에 의해 뒷받침됩니다. 이 회사의 지적 재산권 포트폴리오는 90개 이상의 소유 및 라이센스 특허를 포함합니다. Niagen은 비즈니스 파트너십을 통해 제공되며, 현재 미국에서 가장 선도적인 건강 노화 NAD+ 보충제인 ChromaDex의 Tru Niagen 브랜드의 활성 성분입니다.
ChromaDex Corp. (NASDAQ: CDXC) annonce que son ingrédient breveté nicotinamide riboside (NR), Niagen®, a été sélectionné comme ingrédient clé dans le nouveau complément de Longevity.Technology. Niagen, reconnu comme la référence en matière de suplementation en NAD+, est soutenu par plus de 30 études cliniques humaines révisées par des pairs montrant des bénéfices pour la santé cellulaire, cérébrale, cardiaque et musculaire. Le portefeuille de propriété intellectuelle de l'entreprise comprend plus de 90 brevets détenus et sous licence. Niagen est disponible par le biais de partenariats commerciaux et constitue l'ingrédient actif de la marque Tru Niagen de ChromaDex, actuellement le premier complément pour un vieillissement en bonne santé à base de NAD+ aux États-Unis.
ChromaDex Corp. (NASDAQ: CDXC) gibt bekannt, dass der patentierte Inhaltsstoff Nicotinamid-Ribosid (NR) des Unternehmens, Niagen®, als Hauptbestandteil im neuen Supplement von Longevity.Technology ausgewählt wurde. Niagen, das als der Goldstandard für NAD+-Supplementierung gilt, wird von über 30 von Fachkollegen geprüften Studien zur Verbesserung der Zell-, Gehirn-, Herz- und Muskelfunktion unterstützt. Das geistige Eigentumsportfolio des Unternehmens umfasst über 90 eigene und lizenzierte Patente. Niagen ist über Geschäftspartnerschaften erhältlich und ist der aktive Inhaltsstoff in ChromaDex' Tru Niagen-Marke, die derzeit das führende gesundheitsfördernde NAD+-Supplement in den Vereinigten Staaten ist.
- Leading market position: Tru Niagen is the #1 healthy-aging NAD+ supplement in the US
- Strong IP protection with 90+ owned and licensed patents
- Robust scientific validation with 30+ peer-reviewed human clinical studies
- New business partnership expanding market reach through Longevity.Technology
- None.
Insights
This partnership announcement, while highlighting ChromaDex's leadership in NAD+ supplementation, has immediate financial impact. The deal with Longevity.Technology represents incremental revenue potential but likely won't significantly move the needle for ChromaDex's
The company's robust IP portfolio of 90+ patents and 30+ peer-reviewed clinical studies creates significant barriers to entry. With Tru Niagen already the #1 healthy-aging NAD+ supplement in the US, this partnership expands distribution channels and could help capture more market share in the growing longevity supplement sector.
The gold standard in NAD+ supplementation, Niagen® is a key ingredient for supporting cellular health and promoting healthy aging in Longevity.Technology’s new supplement
Longevity.Technology, a leading media and research organization in the longevity field, launched its consumer division to deliver rigorously validated supplements that address the biological aspects of aging. Longevity.Technology LONGEVITY is the first supplement from this division and integrates a science-backed ingredient stack designed to support mitochondrial health and encourage cellular resilience. With its origins in reference standards, ChromaDex has grown to the forefront of the NAD+ field, making the company an ideal partner for Longevity.Technology.
“Niagen NR is by far the most efficient, safe, and legal precursor among all NAD+ boosters,” said Rob Fried, CEO of ChromaDex and founder of Tru Niagen®. “By choosing Niagen as a hero ingredient in this first supplement, Longevity.Technology is helping to make science-based solutions for healthy aging accessible to a broader audience. We are thrilled to support their mission with our commitment to quality and clinical evidence.”
Backed by the highest scientific and quality standards, Niagen is the most efficient, high-quality NAD+ precursor available. Niagen has over 30 peer-reviewed human clinical studies demonstrating the benefits of elevating NAD+ in key health areas such as cellular, brain, heart, and muscle health. ChromaDex’s robust intellectual property (IP) portfolio of 90+ owned and licensed patents protects Niagen and other NAD+ precursors. Niagen is a food-grade ingredient available through business partnerships, such as with Longevity.Technology, and the active ingredient in ChromaDex’s consumer supplement brand, Tru Niagen, the number one healthy-aging NAD+ supplement in
“After years of reviewing the science behind longevity, we saw the need for products that are grounded in human evidence,” said Dev Heaton, head of Longevity.Technology’s Consumer Division. “Our partnership with ChromaDex ensures that Longevity.Technology LONGEVITY is formulated with the highest standards of scientific validation, giving our customers the confidence that they’re using a supplement proven to support their healthspan.”
Longevity.Technology’s LONGEVITY supplement will be manufactured by ProTab Laboratories, a
For more information on Niagen visit www.chromadex.com and to learn more about Longevity.Technology’s LONGEVITY supplement, please visit www.longevity.technology.com/store.
*Based on the top-selling dietary supplement brands by revenue per the largest
Forward Looking Statements:
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, including statements related to business partners. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as "expects," "anticipates," "intends," "estimates," "plans," "potential," "possible," "probable," "believes," "seeks," "may," "will," "should," "could" or the negative of such terms or other similar expressions. Risks that contribute to the uncertain nature of these forward-looking statements include the impact of the COVID-19 pandemic on our business and the global economy; our history of operating losses and need to obtain additional financing; the growth and profitability of our product sales; our ability to maintain sales, marketing and distribution capabilities; changing consumer perceptions of our products; our reliance on a single or limited number of third-party suppliers; and the risks and uncertainties associated with our business and financial condition. More detailed information about ChromaDex and the risk factors that may affect the realization of forward-looking statements is set forth in ChromaDex's Annual Report on Form 10-K for the fiscal year ended December 31, 2023, ChromaDex's Quarterly Reports on Form 10-Q and other filings submitted by ChromaDex to the SEC, copies of which may be obtained from the SEC's website at www.sec.gov. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and actual results may differ materially from those suggested by these forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement and ChromaDex undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof.
About ChromaDex:
ChromaDex Corp. (NASDAQ:CDXC) is the global authority on nicotinamide adenine dinucleotide (NAD+), with a focus on the science of healthy aging. The ChromaDex team, composed of world-renowned scientists, works with independent investigators from esteemed universities and research institutions around the globe to uncover the full potential of NAD+. A vital coenzyme found in every cell of the human body, NAD+ declines with age and exposure to other everyday stressors. NAD+ depletion is a contributor to age-related changes in health and vitality.
Setting the benchmark as the gold standard in scientific rigor, safety, quality, and transparency, ChromaDex is the innovator behind its clinically proven flagship ingredient, Niagen (patented nicotinamide riboside, or NR), the most efficient and superior-quality NAD+ booster available.
Niagen® is the active ingredient in ChromaDex’s consumer products, sold as the brand Tru Niagen®, the number one healthy-aging NAD+ supplement in
ChromaDex’s robust patent portfolio protects NR and other NAD+ precursors. ChromaDex maintains a website at www.chromadex.com, where copies of press releases, news, and financial information are regularly published.
†Based on the top-selling dietary supplement brands by revenue per the largest
About Longevity.Technology:
Founded in 2019, Longevity.Technology began as a media platform covering science, business and investment activity in the emerging field of longevity. After rapidly becoming one of the sector's leading news services, the company was able to leverage its domain authority to expand its reach into market research, education and ecommerce. www.longevity.technology
View source version on businesswire.com: https://www.businesswire.com/news/home/20241114485647/en/
ChromaDex Media Contact:
Kendall Knysch, Senior Director of Media Relations & Partnerships
310-388-6706 ext. 689
kendall.knysch@chromadex.com
ChromaDex Investor Relations Contact:
Ben Shamsian
Lytham Partners
646-829-9701
shamsian@lythampartners.com
Source: ChromaDex Corporation
FAQ
What is the main ingredient in Longevity.Technology's new supplement featuring ChromaDex (CDXC)?
How many clinical studies support ChromaDex's (CDXC) Niagen ingredient?
What is ChromaDex's (CDXC) market position in NAD+ supplements?
How many patents does ChromaDex (CDXC) have for Niagen?
